Use of Granulocyte-colony Stimulating Factor During Chemotherapy and Its Association With CA27.29 and Circulating Tumor Cells-Results From the SUCCESS A Trial
Hepp P, Fasching P, Beckmann M, Fehm T, Salmen J, Hagenbeck C, Jaeger B, Widschwendter P, De Gregorio N, Schochter F, Mahner S, Harbeck N, Weissenbacher T, Kurt AG, Friedl TWP, Janni W, Rack B (2018)
Publication Type: Journal article
Publication year: 2018
Journal
Book Volume: 18
Pages Range: e1103-e1110
Journal Issue: 5
DOI: 10.1016/j.clbc.2018.06.006
Abstract
Little is known about the effect of granulocyte colony-stimulating factor (G-CSF) treatment during adjuvant chemotherapy on prognostic markers. The present study explored the association between G-CSF and changes in cancer antigen (CA)27.29 and circulating tumor cell (CTC) levels during therapy.A total of 3754 node-positive or high-risk node-negative early-stage breast cancer patients were treated within the SUCCESS-A trial (simultaneous study of gemcitabine-docetaxel combination adjuvant treatment, as well as extended bisphosphonate and surveillance-trial). CA27.29 and CTCs were determined before the start and within 6 weeks after the end of chemotherapy.Overall, 1324 of the 2646 patients (50.0%) available for analysis had >= 1 G-CSF applications during chemotherapy. G-CSF application was significantly associated with CA27.29 status before and after chemotherapy (? = 30.6, df = 3; P < .001), because 238 patients (18.0%) with G-CSF treatment but only 146 (11.0%) without G-CSF treatment switched from a negative CA27.29 status before to a positive CA27.29 status after chemotherapy. In addition, patients with G-CSF application showed a significantly greater increase in CA27.29 levels after chemotherapy compared with patients without any G-CSF application during chemotherapy (Mann-Whitney U test; Z = -7.81, P < .001). No significant association was found between G-CSF application and CTC status before or after chemotherapy (? = 1.2, df = 3; P = .75).Cautious interpretation is needed regarding elevated levels of MUC-1-derived tumor markers such as CA27.29 shortly after adjuvant chemotherapy when G-CSF has been given, because G-CSF treatment was associated with increased CA27.29 levels after chemotherapy.
Authors with CRIS profile
Peter Fasching
Professur für Translationale Frauenheilkunde und Geburtshilfe
Matthias Beckmann
Lehrstuhl für Geburtshilfe und Frauenheilkunde
Involved external institutions
Universität Witten/Herdecke
Germany (DE)
Universitätsklinikum Düsseldorf
Germany (DE)
Universitätsklinikum Ulm
Germany (DE)
Ludwig-Maximilians-Universität (LMU)
Germany (DE)
Germany (DE)
Universitätsklinikum Düsseldorf
Germany (DE)
Universitätsklinikum Ulm
Germany (DE)
Ludwig-Maximilians-Universität (LMU)
Germany (DE)
How to cite
APA:
Hepp, P., Fasching, P., Beckmann, M., Fehm, T., Salmen, J., Hagenbeck, C.,... Rack, B. (2018). Use of Granulocyte-colony Stimulating Factor During Chemotherapy and Its Association With CA27.29 and Circulating Tumor Cells-Results From the SUCCESS A Trial. Clinical Breast Cancer, 18(5), e1103-e1110. https://doi.org/10.1016/j.clbc.2018.06.006
MLA:
Hepp, Philip, et al. "Use of Granulocyte-colony Stimulating Factor During Chemotherapy and Its Association With CA27.29 and Circulating Tumor Cells-Results From the SUCCESS A Trial." Clinical Breast Cancer 18.5 (2018): e1103-e1110.
BibTeX: Download